Placebo-Controlled, Double-Blind, Phase 2/3 Efficacy and Safety Trial of HLCM051 (MultiStem®) in Patients With Ischemic Stroke
Phase of Trial: Phase II/III
Latest Information Update: 22 Feb 2018
At a glance
- Drugs Allogeneic stem cell therapy Athersys (Primary)
- Indications Stroke
- Focus Registrational; Therapeutic Use
- Acronyms TREASURE
- Sponsors Healios
- 16 Feb 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2020.
- 16 Feb 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2020.
- 15 Nov 2017 According to an Athersys media release, first patient has been enrolled.